Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (14,123,107)	$ (5,714,014)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,412	8,521
Stock-based compensation	2,966,603	510,599
Change in fair value of warrants	(19,807)	$ (226,584)
Issuance of restricted common stock for services	1,958,450
Increase (decrease) in operating assets and liabilities:
Grants receivable	(48,974)
Other receivables	2,275	$ 3,629
Prepaid expenses and other	(191,619)	(200,070)
Accounts payable	749,258	599,608
Accrued clinical operations and site costs	(120,913)	(347,031)
Accrued compensation	258,732	(628,623)
Other accrued expenses	636,358	293,014
Net cash used in operating activities	(7,917,332)	(5,700,951)
Investing activities
Purchases of property and equipment	$ (68,279)	(38,744)
Proceeds from acquisition of Telik, Inc.		1,497,283
Net cash provided by (used in) investing activities	$ (68,279)	1,458,539
Financing activities
Issuances of preferred stock, net of issuance costs	2,500,000	2,973,655
Issuances of common stock, net of issuance costs	8,546,348	$ 2,892,615
Proceeds from exercise of stock options	$ 800
Proceeds from exercise of Series B warrant		$ 1,942
Proceeds from exercise of Series C-1 warrant		1,472,502
Net cash provided by financing activities	$ 11,047,148	7,340,714
Net change in cash and cash equivalents	3,061,537	3,098,302
Cash and cash equivalents at beginning of year	1,477,143	354,254
Cash and cash equivalents at end of year	4,538,680	3,452,556
Supplemental disclosure:
Cash paid during the period for income taxes	1,600	800
Supplemental disclosures of non-cash investing and financing information:
Deemed dividend on beneficial conversion feature for preferred stock	$ 17,852,921	2,214,911
Goodwill on acquisition of Telik, Inc.		6,157,681
Accretion of redemption value for Series A-1, B and C-1 convertible preferred stock	$ 93,234	307,216
Issuance of common stock for accounts payable		240,000
Conversion of Series A and Series B redeemable preferred stock into common stock	$ 160,380	12,527,124
Conversion of Series C preferred stock to common stock	$ 966	1,190
Conversion of Series C-1 redeemable preferred stock into Series A-1 preferred stock		$ 6,807,388
Conversion of Series D preferred stock to common stock	$ 467
Conversion of Series A-1 redeemable preferred stock into common stock	162,968
Exchange of Series A-1 preferred stock and warrants into common stock and Series D convertible preferred stock	13,111,280
Exchange of Series B preferred stock and warrants into common stock and Series D convertible preferred stock	10,451,784
Warrants exercised to purchase common stock on a cashless basis	$ 12,198	$ 2,760
Change in fair value of warrant liability in connection with issuance of warrants with Series B preferred stock		$ 226,584
Elimination of warrant liability in exchange transaction	$ 72,656
Financing costs not yet paid	$ (586,608)